Oncology

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR...

1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR...

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events...

1. In patients with previously treated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with sacituzumab...

1. In this retrospective cohort study, age-specific incidence rates of appendiceal adenocarcinoma increased by time period. 2. Local drift for...

1. In this Australian cohort of adults, individuals diagnosed with cancer experienced greater declines in physical functioning and slightly higher...

1. Among patients with active cancer and prior venous thromboembolism (VTE), extended treatment with reduced-dose apixaban demonstrated noninferior efficacy to...

1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade...

1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the...

1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the...